# A Study of MG2512 Injection in Participants With Advanced Solid Tumors

> **NCT07348653** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.** · enrollment: 116 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** MG2512 Injection

## Key facts

- **NCT ID:** NCT07348653
- **Lead sponsor:** Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348653, "A Study of MG2512 Injection in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07348653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*